Trial Profile
KOBE Study of Pioglitazone Effective in Preventing Restenosis after Endovascular Therapy
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 14 May 2016
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary) ; Antihyperglycaemics
- Indications Restenosis; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms KOBE-SPEED
- 14 May 2016 New trial record